Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Artificial Intelligence in Precision Medicine Market Demand Across Healthcare ApplicationsThe Artificial Intelligence in Precision Medicine Market is entering a high-growth phase as healthcare providers and pharmaceutical companies increasingly use AI to understand disease biology, [read full press release...]
- Microvascular Therapeutics Selected to Present Investment Opportunity at ACQUICON 2026Microvascular Therapeutics, Inc. (“MVT”), a clinical-stage biotechnology company developing next-generation ultrasound imaging and therapeutic technologies, today announced that it has been selected to present in the ACQUICON 2026 Deal Room on Tuesday, October 20, 2026, from 12:30–1:30 p.m. Mountain Time at the Karen Gail Miller Conference Center in Salt Lake City. [PR.com]
- Recent Release, "One Couple, Two Badges," from Page Publishing Author Sean Michaels, Chronicles a True Battle Against a Dangerous Criminal EnterpriseSean Michaels has completed a new book, "One Couple, Two Badges," a gripping account of two DEA agents whose partnership transformed from professional collaboration into an unbreakable bond forged in danger. Beginning as independent operatives working in tandem against street-level drug distribution, these agents soon recognized that dismantling the infrastructure at ground level would never achieve lasting [PR.com]
- Global Digital Biomarkers Market Size, Share, Competitive Landscape, and Forecast - 2033 | AI and Remote Monitoring Drive 13.80% CAGR Toward USD 18.1 BillionDigital biomarkers can reduce clinical trial costs, improve compliance and outcomes, while remote monitoring lowers hospital readmissions and supports personalized care
- Alvotech og Advanz Pharma fyrst til að sækja um markaðsleyfi fyrir hliðstæðu við augnlyfið Eylea í háum styrkREYKJAVÍK (14. október 2026) - Alvotech (NASDAQ: ALVO, ALVO SDB) og Advanz Pharma hafa lagt inn umsókn til Lyfjastofnunar Evrópu (EMA) um markaðsleyfi fyrir fyrirhugaða hliðstæðu við augnlyfið Eylea (aflibercept) í háum styrk, 8 mg. Þetta er í fyrsta sinn sem sótt er um markaðsleyfi einhverstaðar í heiminum fyrir hliðstæðu við Eylea í þessum styrkleika, samkvæmt opinberum upplýsingum.
- Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mgAVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg)
- Equity InsiderCancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research AgendaEquity Insider News Commentary - Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, according to the IQVIA Institute, with the United States accounting for roughly 46% of the total. The...
- Nxera Pharma Enters into Exclusive License, Supply and Commercialization Agreement with Synmosa for QUVIVIQ® (daridorexant) Across Eight Asia-Pacific MarketsTokyo, Japan and Cambridge, UK, 14 October 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”; TSE: 4565) today announces that its subsidiary, Nxera Pharma Japan Co., Ltd. (“Nxera Pharma Japan”), has entered into an exclusive license, supply and commercialization agreement (the “Agreement”) with Taiwan-headquartered Synmosa Biopharma Corporation (“Synmosa”) for QUVIVIQ® (daridorexant), a treatment for insomnia, in Singapore, Thailand, Indonesia, Malaysia, the Philippines, Vietnam, Australia and New Zealand (the “Territory”).
- MindMaze Therapeutics Holding SAMindMaze Therapeutics Reports New Home-Based Rehabilitation Results Ahead of MindMotion Lite LaunchMulti-site program demonstrates threefold increase in rehabilitation training dose, with 84% delivered independently and significant improvements across functional measures — MindMaze Therapeutics (SIX: MMTX), a global leader in scalable precision...
- Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANMTelix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that 20 company-related abstracts will be presented at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM) to be...
- THE ROSEN LAW FIRM, P. A.Unicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud LawsuitWhy: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November...
- Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity-- Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance drug price list -- -- IMCIVREE is the first approved therapy in Japan for patients living with acquired hypothalamic obesity --